Home > Dangerous Drugs > Nephrogenic Systemic Fibrosis (NSF) > Gadolinium

Gadolinium detected in NSF patients body tissues

written by John M. Restaino, Jr., DPM, J.D.

Researchers at the University of Colorado Health Sciences Center, the Colorado School of Mines and Yale University Medical Center have detected gadolinium particles within the body tissue of patients diagnosed with Nephrogenic Systemic Fibrosis (NSF). NSF was first reported in 1997 as a disease of unknown cause that affects a patient with renal insufficiency who have been exposed to gadolinium-containing contrast agents during MRI examinations. Most of the cases reported within the world's medical literature have linked the disease with General Electric's Omniscan contrast medium though cases have also been reported with other contrast agents.

Click to read the report done by Mike TeSelle, KCRA 3, Sacramento, CA:
"Some Kidney Patients Suffer MRI Poisoning
– Dye Containing Gadolinium Blamed For Problems"

Click to view our video about "Gadolinium Dyes"

Click to view our video about "Nephrogenic Systemic Fibrosis"

View our NSF brochure for more information

Click to read the report done by Correy E. Stephenson, Lawyers USA:
"Gadolinium litigation heats up"

These researchers studied paraffin wax-embedded skin and soft tissue from NSF patients exposed to gadolinium, and from negative controls. The materials were provided by the NSF International Registry overseen by Dr. Shawn Cowper, Yale University Medical center, New Haven, Connecticut. Under the direction of Dr. Whitney High, a dermatologist and dermatopathologist at the University of Colorado Health Sciences Center, the tissue was searched for metals using a field emission scanning electron microscope that was equipped with energy dispersive spectroscopy. The presence of gadolinium and other metals was verified through identification of unique and requisite X-ray emission spectra.

Nephrogenic Systemic Fibrosis (NSF)

The Little-Known Debilitating and Deadly Danger of MRIs

Gadolinium and NSF/NFD

Preventing NSF/NFD

The Effects of NSF/NFD

Treating NSF/NFD

Frequently Asked Questions About
Nephrogenic Systemic Fibrosis (NSF) Lawsuits

The researchers reported that the data indicate a significant amount of gadolinium within the skin and soft tissue of patients with NSF, ranging from 5 to 106 ppm when the unexposed person would be expected to have < 1 ppm or zero gadolinium within their body. Comparing their results to a previous study evaluating the presence of gadolinium within the bone of healthy volunteers, the Colorado/Yale researchers noted that the amount of gadolinium in the affected tissue of patients with NSF is approximately 35- to 150-fold higher than that seen in the healthy volunteers with normal renal function.

References:
High WA, Ayers RA, Cowper SE. Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007 Apr;56(4):710-2

High WA, Ayers RA, Chandler J, Zito G, Cowper SE. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol. 2007 Jan;56(1):21-6. Epub 2006 Nov 9.

Colorado Wyoming Ohio Arizona

Gadolinium detected in NSF patients body tissues

written by John M. Restaino, Jr., DPM, J.D.

$5,350,000

$1,300,000

$690,000,000

$5,800,000